These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26329438)

  • 21. [Restless legs: recent advances in basic research and therapy].
    Sieb JP
    Med Monatsschr Pharm; 2010 Apr; 33(4):133-9. PubMed ID: 20429403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Augmentation in restless legs syndrome patients in Korea.
    Jeon JY; Moon HJ; Song ML; Lee HB; Cho YW
    Sleep Breath; 2015 May; 19(2):523-9. PubMed ID: 25082663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep.
    Vignatelli L; Billiard M; Clarenbach P; Garcia-Borreguero D; Kaynak D; Liesiene V; Trenkwalder C; Montagna P;
    Eur J Neurol; 2006 Oct; 13(10):1049-65. PubMed ID: 16987157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?
    Heim B; Djamshidian A; Heidbreder A; Stefani A; Zamarian L; Pertl MT; Brandauer E; Delazer M; Seppi K; Poewe W; Högl B
    Neurology; 2016 Jul; 87(1):36-40. PubMed ID: 27261093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome.
    Silber MH; Becker PM; Earley C; Garcia-Borreguero D; Ondo WG;
    Mayo Clin Proc; 2013 Sep; 88(9):977-86. PubMed ID: 24001490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment.
    Garcia-Borreguero D; Cano-Pumarega I; Garcia Malo C; Cruz Velarde JA; Granizo JJ; Wanner V
    Sleep Med; 2019 Mar; 55():74-80. PubMed ID: 30772697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopaminergic Therapy for Restless Legs Syndrome/Willis-Ekbom Disease.
    Zak RS; Walters AS
    Sleep Med Clin; 2015 Sep; 10(3):279-85, xiii. PubMed ID: 26329437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In search of alternatives to dopaminergic ligands for the treatment of restless legs syndrome: iron, glutamate, and adenosine.
    Ferré S; Earley C; Gulyani S; Garcia-Borreguero D
    Sleep Med; 2017 Mar; 31():86-92. PubMed ID: 27899234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic advances in restless legs syndrome (RLS).
    Högl B; Comella C
    Mov Disord; 2015 Sep; 30(11):1574-9. PubMed ID: 26371624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical data on restless legs syndrome: a dose-finding study with cabergoline.
    Stiasny K
    Eur Neurol; 2001; 46 Suppl 1():24-6. PubMed ID: 11741100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Parkinson's disease and restless legs syndrome/Willis-Ekbom disorder link: evidences, biases and clinical relevance.
    Munhoz RP; Constantino MCL; Silveira-Moriyama L
    Arq Neuropsiquiatr; 2019 Jan; 77(1):47-54. PubMed ID: 30758442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gabapentin enacarbil (XP13512/GSK1838262) as an alternative treatment to dopaminergic agents for restless legs syndrome.
    Imamura S; Kushida C
    Expert Opin Pharmacother; 2010 Aug; 11(11):1925-32. PubMed ID: 20629607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of restless legs syndrome.
    Comella CL
    Neurotherapeutics; 2014 Jan; 11(1):177-87. PubMed ID: 24363103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks.
    García-Borreguero D; Högl B; Ferini-Strambi L; Winkelman J; Hill-Zabala C; Asgharian A; Allen R
    Mov Disord; 2012 Feb; 27(2):277-83. PubMed ID: 22328464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Willis-Ekbom Disease or Restless Legs Syndrome?
    Carlos K; Prado LB; Carvalho LB; Prado GF
    Sleep Med; 2015 Sep; 16(9):1156-9. PubMed ID: 26298794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targinact for restless legs syndrome.
    Drug Ther Bull; 2016 Apr; 54(4):42-5. PubMed ID: 27079737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current guidelines and standards of practice for restless legs syndrome.
    Hening WA
    Am J Med; 2007 Jan; 120(1 Suppl 1):S22-7. PubMed ID: 17198767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rate of augmentation and risk factors with long-term follow-up in Japanese patients with restless legs syndrome.
    Tanioka K; Okura M; Inoue M; Taniguchi KI; Taniguchi M; Hamano T; Tachibana N
    Neurol Sci; 2018 Sep; 39(9):1559-1564. PubMed ID: 29845566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes of cortical excitability after dopaminergic treatment in restless legs syndrome.
    Scalise A; Pittaro-Cadore I; Janes F; Marinig R; Gigli GL
    Sleep Med; 2010 Jan; 11(1):75-81. PubMed ID: 19595629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sleep Disorders: Restless Legs Syndrome.
    Burman D
    FP Essent; 2017 Sep; 460():29-32. PubMed ID: 28845959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.